Billiontoone (NASDAQ:BLLN) Sets New 12-Month Low – Here’s What Happened

Billiontoone, Inc. (NASDAQ:BLLN) reached a new 52-week low during trading on Wednesday . The company traded as low as $81.26 and last traded at $81.40, with a volume of 243156 shares trading hands. The stock had previously closed at $85.09.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. William Blair assumed coverage on shares of Billiontoone in a research report on Monday, December 1st. They issued an “outperform” rating on the stock. Wall Street Zen raised shares of Billiontoone to a “hold” rating in a research note on Saturday, November 15th. Piper Sandler reiterated an “overweight” rating on shares of Billiontoone in a report on Wednesday, December 10th. BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Billiontoone in a report on Wednesday, December 10th. Finally, Zacks Research raised Billiontoone to a “hold” rating in a research report on Tuesday, December 2nd. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Billiontoone has a consensus rating of “Moderate Buy” and a consensus target price of $137.83.

Billiontoone Stock Performance

The stock has a market capitalization of $3.71 billion and a PE ratio of 810.40.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Tuesday, December 9th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.06). The company had revenue of $83.52 million for the quarter, compared to analyst estimates of $82.86 million.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.